10 x Humatrope Lilly 72iu

10 x Humatrope Lilly 72iu Classification

Humatrope Lilly 72iu is a prescription-only medicine containing somatropin, a recombinant human growth hormone (r-hGH) used for clinically diagnosed growth hormone deficiency in adults and specific paediatric growth disorders, supplied here in the 24mg (72IU) cartridge format designed for subcutaneous injection using compatible pen systems. In the UK and EU, somatropin is classified under pituitary and hypothalamic hormones (ATC H01AC01), with pharmacological actions equivalent to endogenous human growth hormone, impacting growth plates, protein synthesis, lipid metabolism, and body composition. The Humatrope range historically included 6mg, 12mg, and 24mg cartridges; however, UK medicines supply notices confirm Humatrope cartridges have been discontinued with stock exhaustion in late April 2024, and patients are typically switched to alternative licensed somatropin brands where appropriate under specialist guidance. Despite discontinuation notices, detailed prescribing frameworks, contraindications, precautions, and dosing paradigms for somatropin remain relevant for clinical decision-making and safe patient use under NHS shared-care arrangements.

Prescription-only medicine for diagnosed growth hormone deficiency and specific paediatric indications.

• Pharmacotherapeutic group: Somatropin and somatropin agonists (ATC H01AC01).
• 24mg (72IU) single-patient cartridge intended for subcutaneous delivery with rotation of injection sites.
• UK supply update: Humatrope cartridges discontinued; other somatropin brands available via NHS pathways.

What is Humatrope Lilly 72iu?

Humatrope Lilly 72iu is Eli Lilly’s recombinant human growth hormone, somatropin, formulated as a white lyophilised powder in a single-patient-use 24mg (72IU) cartridge for reconstitution and subcutaneous injection. The amino acid sequence is identical to endogenous pituitary GH, designed to replace or supplement deficient growth hormone to normalise metabolic processes and, in children, support linear growth. It is indicated in adults for growth hormone deficiency and in paediatric populations for conditions including inadequate endogenous GH secretion, Turner syndrome, short stature homeobox-containing gene (SHOX) deficiency, idiopathic short stature, and children born small for gestational age who fail catch-up growth, as defined in official labelling. Administration requires a compatible pen device and adherence to reconstitution and injection instructions, with dosing titrated by a specialist based on clinical response and IGF-1 targets.

• 24mg (72IU) somatropin cartridge for subcutaneous use after reconstitution.
• Bioidentical to human GH; restores GH-dependent metabolic and growth functions.
• Adult indication: replacement therapy in GH deficiency; paediatric indications per label.
• Delivered via compatible pens with specialist-directed dosing and monitoring.

Recommended Dosage for Humatrope Lilly 72iu

Dosing is individualised and prescribed by a healthcare professional, with specific regimens differing for adults and children; adult therapy typically starts low and titrates to clinical effect and IGF-1 within the age-adjusted normal range.

• Adult non-weight-based: initiate ~0.2mg/day (range 0.15–0.3mg/day), increase by 0.1–0.2mg/day every 1–2 months based on clinical response and IGF‑1; avoid excessive dosing, especially in older or obese adults.
• Adult weight-based (not recommended in obesity): start 0.006mg/kg daily, titrate to a maximum 0.0125mg/kg daily as needed.
• Paediatric dosing: total weekly dose divided into 6–7 injections, with exact mg/kg dosing per indication and specialist direction.
• Injection sites: back of upper arm, abdomen, buttock, or thigh; rotate sites to reduce lipoatrophy risk.
• Always follow specialist titration to minimise side effects such as fluid retention and to maintain IGF‑1 within target range.

How Does Humatrope Lilly 72iu Work?

Somatropin binds to growth hormone receptors and stimulates the production of insulin-like growth factor 1 (IGF‑1), mediating anabolic and growth-promoting effects across tissues. It accelerates chondrocyte proliferation at epiphyseal growth plates in children, increases protein synthesis, reduces nitrogen loss, improves lipid profiles by raising HDL and lowering total cholesterol, and shifts body composition by decreasing fat mass and increasing lean body mass. In adults with GH deficiency, long-term therapy improves bone mineral density and body composition, supporting functional capacity and metabolic health.

• Stimulates IGF‑1 and chondrocyte activity to promote linear growth in children.
• Enhances protein synthesis and nitrogen retention; improves lipid metabolism.
• Reduces adiposity and increases lean mass; improves BMD with sustained treatment.
• May induce insulin resistance; glucose tolerance can be affected, requiring monitoring.

Benefits of Taking Humatrope Lilly 72iu

When clinically indicated and supervised, somatropin replacement offers targeted benefits that address the physiological deficits of GH deficiency.

• In children: improved growth velocity, potential normalisation of adult height in select indications, and favourable body composition changes.
• In adults: reduction in fat mass, increase in lean body mass, improved bone mineral density over time, and improved metabolic parameters.
• Quality-of-life improvements may be observed in appropriately selected adults with confirmed severe GH deficiency as part of comprehensive care.
• Benefits rely on correct diagnosis, dosing titration, and regular monitoring to balance efficacy with safety.

When should you take Humatrope Lilly 72iu?

Somatropin is administered once daily by subcutaneous injection, with timing tailored by the clinician to adherence and tolerability; many regimens favour evening dosing to physiologically align with nocturnal GH secretion, though this is not mandatory in labelling. Paediatric regimens divide weekly totals into 6–7 doses to ensure steady exposure, and adults follow daily dosing schedules with gradual titration. Site rotation every injection helps reduce local reactions and lipoatrophy.

• Daily subcutaneous injection at a consistent time as advised by the prescribing specialist.
• Rotate between abdomen, thigh, buttock, or arm injection sites.
• Adherence to the prescribed schedule is essential for efficacy and safety.

When Should You Not Take Humatrope Lilly 72iu?

Somatropin has explicit contraindications and clinical scenarios where treatment must be avoided or temporarily stopped.

• Acute critical illness after open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure due to increased mortality at pharmacologic doses.
• Active malignancy; therapy should be stopped in the presence of tumour activity.
• Active proliferative or severe non-proliferative diabetic retinopathy.
• Known hypersensitivity to somatropin or excipients.
• Paediatric patients with closed epiphyses (no linear growth potential).
• Paediatric Prader–Willi syndrome with severe obesity, sleep apnoea, or severe respiratory impairment due to risk of sudden death.
• UK shared-care guidance further cautions use post-renal transplantation in seriously ill patients and advises avoidance during pregnancy unless specialist benefits outweigh risks.

What is the Mechanism of Humatrope Lilly 72iu

Mechanistically, somatropin is a 191–amino acid peptide identical to native human GH that binds the GH receptor, activating JAK2/STAT pathways and inducing hepatic and local IGF‑1, which drives cartilage growth, protein synthesis, and metabolic modulation. Pharmacodynamically, it increases IGF‑1 and IGFBP‑3, enhances lipolysis with reduced total cholesterol and increased HDL, improves nitrogen balance, and over time increases bone mineral density in GH-deficient patients. High doses can produce insulin resistance and impair glucose tolerance, underscoring the need for careful dosing and glucose monitoring.

• GH receptor activation leads to IGF‑1–mediated growth and anabolic effects.
• Alters lipid and glucose metabolism; requires monitoring for insulin resistance.

Uses of Humatrope Lilly 72iu

Humatrope’s licensed uses include adult and paediatric indications as defined by regulatory labelling.

• Adults: replacement therapy for confirmed growth hormone deficiency.
• Children: growth failure due to inadequate endogenous GH secretion, Turner syndrome, SHOX deficiency, idiopathic short stature meeting SDS criteria, and SGA children without catch‑up growth by 2–4 years.
• Treatment decisions, initiation, and continuation typically follow specialist assessment pathways (e.g., NICE criteria and NHS shared-care where applicable).

Warnings and Precautions for Humatrope Lilly 72iu

Careful patient selection, baseline assessment, and ongoing monitoring are essential.

• Acute critical illness: increased mortality in ICU patients at pharmacological doses—do not initiate; reassess if such conditions develop.
• Neoplasia: discontinue with evidence of tumour activity; ensure intracranial lesions inactive before starting; monitor for recurrence.
• Glucose metabolism: may induce insulin resistance; monitor glucose/HbA1c; adjust antidiabetic therapies as needed.
• Thyroid function: somatropin may unmask or worsen hypothyroidism; periodic TFT monitoring recommended.
• Intracranial hypertension: monitor for severe/recurrent headache, visual changes, nausea/vomiting; evaluate for papilloedema and adjust therapy.
• Slipped capital femoral epiphysis and scoliosis progression: monitor paediatric patients with new limping or hip/knee pain.
• Oedema, arthralgia, carpal tunnel: often dose-related; dose adjustments may be required.
• Pancreatitis: consider in patients with abdominal pain.
• Injection-site reactions and lipoatrophy: rotate injection sites consistently.

Side Effects of Humatrope Lilly 72iu

Adverse reactions vary with dose and patient factors; most are manageable with titration.

• Very common/common: fluid retention, peripheral oedema, arthralgia, myalgia, paraesthesia, injection-site reactions.
• Metabolic: insulin resistance, hyperglycaemia; rarely hypoglycaemia associations noted but causal link not established.
• Neurological: headache; rare benign intracranial hypertension with papilloedema—requires evaluation and management.
• Musculoskeletal: carpal tunnel syndrome (adults), slipped capital femoral epiphysis risk in paediatrics; scoliosis progression monitoring.
• Endocrine: potential hypothyroidism—monitor TFTs; antibody formation has been reported.
• Report suspected adverse effects via MHRA Yellow Card in the UK and liaise with the specialist team for management.

Drug Interactions of Humatrope Lilly 72iu

Somatropin may alter the pharmacokinetics or pharmacodynamics of certain medicines.

• Glucocorticoids: systemic corticosteroids can inhibit growth-promoting effect; consider dose adjustments and monitor growth response.
• Oestrogens: oral oestrogen therapy may reduce GH efficacy—higher somatropin doses may be required; HRT at low doses is less likely to interact, but monitoring is advised.
• CYP3A4 substrates: potential increased clearance of drugs such as anticonvulsants and ciclosporin; monitor clinical effect and drug levels where appropriate.
• Antidiabetic agents: insulin or oral hypoglycaemic requirements may change due to reduced insulin sensitivity—monitor and adjust therapy.
• Always review the full medication list with the prescriber to manage interactions safely.

Storage for Humatrope Lilly 72iu

Follow device-specific instructions for reconstitution and storage to maintain potency and sterility.

• Store cartridges per manufacturer instructions; once reconstituted, keep refrigerated and use within the specified in-use period per device leaflet and label.
• Do not freeze; protect from light; inspect solution for clarity before injection.
• Use compatible pen devices only and follow pen user manuals for priming, dosing, and needle changes.
• Proper storage and handling preserve efficacy and reduce contamination risk.

Where to buy Humatrope Lilly 72iu?

In the UK, somatropin therapy is initiated and supervised by an NHS specialist with shared‑care arrangements for ongoing prescriptions; medicines are dispensed via NHS hospital or community pharmacy services using licensed UK supply chains, ensuring product authenticity and cold-chain integrity. As per the Scottish national medicines supply alert, Humatrope cartridges (6mg, 12mg, 24mg) have been discontinued with stock exhausted in late April 2024, and alternative somatropin brands remain available to support clinical need under specialist guidance. For private patients, supply must still come from UK‑licensed pharmacies against a valid prescription, with the specialist selecting an appropriate currently available somatropin brand and device system.

• Specialist-initiated therapy with UK-licensed products via NHS or private pharmacies.
• Humatrope cartridges discontinued in the UK; prescribers typically transition patients to alternative licensed somatropin brands.

At Buying Steroids UK, we work with qualified prescribers to provide access to genuine, UK‑licensed somatropin alternatives. Our service ensures that every product is sourced through approved UK supply chains, stored correctly, and dispensed only against a valid prescription — so patients can continue their growth hormone therapy safely and seamlessly.

Frequently Asked Questions

Q: Is Humatrope Lilly 72iu still available in the UK?
A: National supply notices confirm Humatrope 6mg, 12mg, and 24mg cartridges have been discontinued with stock exhausted late April 2024 in the UK; clinicians generally switch patients to other licensed somatropin brands that can meet demand.

Q: What conditions does Humatrope treat?
A: Adults with confirmed GH deficiency and children with specified indications including GH deficiency, Turner syndrome, SHOX deficiency, idiopathic short stature meeting criteria, and SGA without catch‑up growth between 2–4 years—per official labelling and specialist assessment.

Q: How is Humatrope dosed for adults?
A: Typically start at ~0.2mg daily and titrate every 1–2 months by 0.1–0.2mg/day to clinical effect and IGF‑1 targets; an alternative weight‑based start (0.006mg/kg daily) is not recommended for obese patients.

Q: What are key safety warnings?
A: Do not use in acute critical illness, active malignancy, active proliferative/severe non‑proliferative diabetic retinopathy, or in children with closed epiphyses; paediatric Prader‑Willi patients with severe obesity or respiratory compromise should not receive somatropin due to sudden death risk.

Q: What side effects should be monitored?
A: Fluid retention, oedema, arthralgia, carpal tunnel in adults, headache and rare benign intracranial hypertension, glucose intolerance, and potential hypothyroidism; paediatric risks include slipped capital femoral epiphysis and scoliosis progression.

Q: Are there drug interactions?
A: Systemic glucocorticoids can blunt growth effects; oral oestrogens may necessitate higher GH doses; somatropin may increase clearance of certain CYP3A4‑metabolised medicines such as anticonvulsants and ciclosporin; antidiabetic regimens may require adjustment.

Q: How should it be stored and used?
A: Reconstitute and administer with a compatible pen; store refrigerated, avoid freezing, protect from light, and follow in‑use time limits and site rotation.

Q: What if a dose is missed?
A: Follow the specialist’s advice; generally, take the next dose at the usual time without doubling, and maintain consistent daily administration—seek guidance for repeated missed doses.

Q: Can athletes use somatropin to enhance performance?
A: Somatropin is a prescription medicine for defined medical indications; non‑medical performance enhancement is not an approved use and may contravene anti‑doping regulations and medical ethics; treatment must be supervised by a specialist within licensed indications.

Q: How does UK care work for adult GH deficiency?
A: NHS shared‑care guidelines outline that initiation and oversight remain with the specialist, with GPs assisting in prescribing and monitoring under defined criteria and communication pathways, ensuring safe, evidence‑based use.